DDI Marker Studies Knowledgebase – quarterly update

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in April 2023, and is available in the DIDB Resource Center.

In this update, 38 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 6 compounds (16%) could lead to strong drug interactions mediated by CYP3A and CYP2D6.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – February Summary

In February, we added 94 citations in DIDB, including 38 in vitro (with 16 articles published in February 2023) and 56 in vivo articles (with 38 articles published in February 2023).

Seven recently approved NDAs and BLAs were also added: anacaulase (NEXOBRID), bexagliflozin (BRENZVVY), lecanemab (LEQEMBI), lenacapavir (SUNLENCA), mosunetuzumab (LUNSUMIO), ublituximab (BRIUMVI), xenon Xe-129 hyperpolarized (XENOVIEW). 

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Our first EUA, paxlovid, available in DIDB

We are pleased to announce the inclusion of FDA-issued Emergency Use Authorization (EUA) data in DIDB for PAXLOVID (nirmatrelvir and ritonavir) authorized for Covid-19 treatment.

Our DIDB editorial team has curated and entered in DIDB, all relevant pharmacokinetic (food effect, hepatic impairment, …) and drug interaction data (CYP3A, P-gp, …) obtained from CDER reviews. 

You can review PAXLOVID comprehensive DDI drug monograph and search preclinical and clinical studies, case reports, modeling and simulation data of this combination drug and its components using various DIDB queries after login to DIDB and access the data here: https://lnkd.in/gr5QkpJK

Data Curation and Entry in DIDB – January Summary

In January, we added 121 citations in DIDB, including 58 in vitro (with 26 articles published in January 2023) and 63 in vivo articles (with 33 articles published in January 2023).

Two recently approved NDAs and BLAs were also added: adagrasib (KRIAZATI), teplizumab (TZIELD) 

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – December Summary

In December, we added 94 citations in DIDB, including 50 in vitro (with 22 articles published in December 2022) and 44 in vivo articles (with 37 articles published in December 2022).

Three recently approved NDAs and BLAs were also added: mirvetuximab soravtansine (ELAHERE), olutasidenib (REZLIDHIA), sodium phenylbutyrate and taurursodiol (RELYVRIO) 

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

DDI Marker Studies Knowledgebase – quarterly update

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in January 2023, and is available in the DIDB Resource Center.

We continue to expand the Knowledgebase by adding more transporter data. In this update, 18 compounds were identified as substates/inhibitors/inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 2 compounds could lead to strong drug interactions.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – November Summary

In November, we added 119 citations in DIDB, including 61 in vitro (with 24 articles published in November 2022) and 58 in vivo articles (with 34 articles published in November 2022).

Three recently approved NDAs and BLAs were also added: futibatinib (LYTGOBI), teclistamab (TECVAYLI), tremelimumab (IMJUDO).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – October Summary

In October, we added 134 citations in DIDB, including 51 in vitro (with 29 articles published in October 2022) and 83 in vivo articles (with 40 articles published in October 2022).

Five recently approved NDAs and BLAs were also added: daxibotulinumtoxina (DAXXIFY), deucravacitinib (SOTYKTU), eflapegrastim (ROLVEDON), omidenepag isopropyl (OMLONTI), and terlipressin (TERLIVAZ).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

Data Curation and Entry in DIDB – September Summary

In September, we added 137 citations in DIDB, including 70 in vitro (with 36 articles published in September 2022) and 67 in vivo articles (with 40 articles published in September 2022).

Two recently approved BLAs were also added: olipudase alfa (XENPOZYME), spesolimab (SPEVIGO).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

DDI Marker Studies Knowledgebase – quarterly update

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in October 2022, and is available in the DIDB Resource Center.

We continue to expand the Knowledgebase by adding more transporter data. In this update, 42 compounds (including 13 endogenous biomarkers) were added as OATP1B/1B3 substrates based on clinical DDI data and/or pharmacogenetic findings. In addition, 16 compounds were identified as substates/inhibitors/inducers of CYP enzymes and transporters (P-gp and BCRP). Among them, 20% could lead to strong drug interactions.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.